Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献64篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NFGzWG9EgXSxdH;4bYMhSXO|YYm= Ml;aNVAhdk1? MkDOO|IhcA>? NHLBR41FVVOR M{LyOHBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> MofkNlQ6ODB6N{O=
HT-29 MX7DfZRwfG:6aXOgRZN{[Xl? MkTPNVAhdk1? NWDm[nB7PzJiaB?= MUXEUXNQ M2njPHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MlvkNlQ6ODB6N{O=
HT-29 MkfpR5l1d3SxeHnjJGF{e2G7 MkDjNVAhdk1? M3z6OVczKGh? M{PLdGROW09? NVvK[FY4WG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? MWmyOFkxODh5Mx?=
PC3 NGnPPW5McW6jc3WgRZN{[Xl? M2XVSlExOCCwTR?= M1PGSVEhcA>? MkO3SG1UVw>? MXzQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= M1vpZ|IyQTd6Nkiz
PC3 MXLLbY5ie2ViQYPzZZk> MVixNFAhdk1? MknVNUBp MWfEUXNQ MnTtSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? M3:wPFIyQTd6Nkiz
PC3 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zSUVEvPSEQvF2= NV3WO4tbOSCq Mn3xSG1UVw>? MYfJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? MWKyNVk4QDZ6Mx?=
HEK293 M4fFfGZ2dmO2aX;uJGF{e2G7 MmrrNVAxKG6P Mn\HPEBp M4fxNWROW09? MlSyTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P NFrEWIgzOTV|OUOwNS=>
BT-20 MXLLbY5ie2ViQYPzZZk> NEfwRXkzOCEQvF2= MlGwSG1UVw>? NInKWJhFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NUDMeFRPOjF|NUO1OVE>
U937 NYm2ZXNISW62aXLhZ5RmemmjbDDBd5NigQ>? MkTaOVAh|ryP M3zqdlQ5KGh? Mmf6SG1UVw>? NVLWcZFvUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz M1Puc|IyOTR{MUC2
U937 M4fGOWFvfGmkYXP0[ZJq[WxiQYPzZZk> NW\vdVFoPTBizszN NGrVW4g1QCCq NVzBWodUTE2VTx?= NV7OblVWTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= MkW3NlEyPDJzME[=
U937 NU\SUIVvSW62aXLhZ5RmemmjbDDBd5NigQ>? NEXhSW42OCEQvF2= NXr5bZh{PDhiaB?= NEX2cHFFVVOR MXjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MVWyNVE1OjFyNh?=
MCF-7 MYfBeZRweGijZ4mgRZN{[Xl? MU[zNEBvVQ>? M1TkVFQhcA>? MX7EUXNQ Mn34TY5lfWOnczDheZRweGijZ4m= NVnDOGcxOjByMkixN|Q>
U87MG MU\LbY5ie2ViQYPzZZk> M1vkNVEh|ryP NGTFWoc3KGh? M3nyN2ROW09? MUjQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? M{\WcVE6QDR6NEC0
U87MG M1z5TGtqdmG|ZTDBd5NigQ>? MkixNUDPxE1? MU[2JIg> MUnEUXNQ MXvQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NXvCOoVvOTl6NEi0NFQ>
U87MG MX7LbY5ie2ViQYPzZZk> MoCwNUDPxE1? M4HXWVYhcA>? MUPEUXNQ M1r4SGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MoTMNVk5PDh2MES=
U87MG Mo[wT4lv[XOnIFHzd4F6 NF3lboYyKM7:TR?= M4LYO|YhcA>? MlXoSG1UVw>? NH\sWY1Fd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? M37GeVE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb M3PxemF2fG:yaHHnfUBCe3OjeR?= NVjkdWRZOC5{IN88US=> NHXUSGczPCCq MWHEUXNQ MoDMTY5lfWOnczDheZRweGijZ4m= MWCxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 MkX3RZV1d3CqYXf5JGF{e2G7 MmfzNE4zKM7:TR?= MYqyOEBp NIXSTYhFVVOR MmTXTY5lfWOnczDheZRweGijZ4m= M3H6ZlE5OzlzOUS5
H4 NWCyW2lGTnWwY4Tpc44hSXO|YYm= MYWwMlIh|ryP MXeyOEBp NHH6R3pFVVOR NV2zSoRJUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? MmTCNVgxOjR3OES=
HeLa MoHUSpVv[3Srb36gRZN{[Xl? NUCzZXJKOTByIH7N NVn5O5hlOzZiaB?= MmrISG1UVw>? NHzQVoxKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NUDvVmR1OTd3NkOzPFU>
HeLa M3HiSGZ2dmO2aX;uJGF{e2G7 MXWxNFAhdk1? NELmVpI{PiCq NWDqT2d1TE2VTx?= MVrJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NYHkXXJFOTd3NkOzPFU>
HeLa MmHQSpVv[3Srb36gRZN{[Xl? MX6xNFAhdk1? Ml[wN|YhcA>? M{fSTGROW09? M2Hlfmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NWSwcVRpOTd3NkOzPFU>
SYF M1W1cGZ2dmO2aX;uJGF{e2G7 NI\mRYMyODBibl2= MkjkNlQhcA>? MlHzSG1UVw>? Ml3ITY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NYLLN4RFOTd3NkOzPFU>
SYF MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNFAhdk1? Mlv0NlQhcA>? NGHyOHNFVVOR NFPqbmRKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NFrhSXAyPzV4M{O4OS=>
HEK293T MYHBcpRqfmm{YXygRZN{[Xl? MoTnNUBvVQ>? NHzrO401KGR? NWf1OZRNTE2VTx?= MWPJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M1XLSFE4PDh3NUCx
HEK293T MUnBcpRqfmm{YXygRZN{[Xl? MlezNUBvVQ>? NITx[IM1KGR? NUTXRnRETE2VTx?= MlfYTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= MkPuNVc1QDV3MEG=
PBMC MoK5SpVv[3Srb36gRZN{[Xl? NHfKN4IyKG6P MWexOEBl NFvBbZdFVVOR MVXS[YR2[2W|IFPDVlUh\GWwc3n0fS=> NG\v[YMyPzR6NUWwNS=>
PBMC M4fuOmZ2dmO2aX;uJGF{e2G7 M1zHcFEhdk1? MXqxOEBl M4GwOGROW09? NXmw[ZFKTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NV7ISXQzOTd2OEW1NFE>
HEK293 cells MoHTT4lv[XOnIFHzd4F6 M4TN[FUxKG6P NHHPblI1PSCvaX6= NIXvWG1FVVOR Mo\NTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? M1vH[lE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NIXJbIRHfW6ldHnvckBCe3OjeR?= MYmxNFAhdk1? NHzze2k1KGh? MmDmSG1UVw>? NIXnU29KdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? M4\r[VE4OTJ6Mk[y
Human mixed lymphocyte MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TrU|Uhdk1? MXPEUXNQ M4rV[mlEPTB;MT62JI5ONg>? MkHVNVYyQDV6NkW=
Lewis rat lymph node cells MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojwOUDPxE1? NWe3bXliTE2VTx?= M2PHOGlEPTB;Mj62JO69VQ>? NFHuTG8yPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH2UWVbOTBibl2= NGS0[VE4OiCq Mnu1SG1UVw>? M4j3W2lvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= MV6xNFAzOTl2OB?=
MRK-nu-1 M174eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yVpd7UUN3ME2wMlg1PSCyTR?= MorZV2FPT0WU
OCUB-M NF[zd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILvd5ZKSzVyPUWuNlQheE1? MVTTRW5ITVJ?
SF539 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3tdJlUUUN3ME2xNU43KHCP Moj1V2FPT0WU
ES4 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhWWN1UUN3ME2yNU42KHCP MoP2V2FPT0WU
RL95-2 M4\XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH6XWdGUUN3ME2xNFcheE1? NVzkS5F4W0GQR1XS
LC-2-ad MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR{MzDwUS=> MVrTRW5ITVJ?
Daudi MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHruXlZKSzVyPUSzOEBxVQ>? Ml;uV2FPT0WU
NTERA-S-cl-D1 NVnGcHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jwe2lEPTB;NESzJJBO MVXTRW5ITVJ?
OS-RC-2 NWKwdZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLMTWM2OD14NUKgdG0> MV;TRW5ITVJ?
VA-ES-BJ NWXHS|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD15MkOgdG0> NFTBfoFUSU6JRWK=
GR-ST NUTmWHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH0bFdNUUN3ME24OFYheE1? MlrpV2FPT0WU
SW872 M2X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rObGlEPTB;OES2JJBO NUjleGhWW0GQR1XS
NOS-1 M1rSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLNTWM2OD16N{GgdG0> NYLIelNOW0GQR1XS
MC116 M1nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzzNIM2UUN3ME25PFUheE1? NXewVHY5W0GQR1XS
NCI-H1355 NXP1PJdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHwd|RKUUN3ME2xMlAyKG6P MYPTRW5ITVJ?
RPMI-8226 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXaZWxDUUN3ME2xMlE6KG6P MVfTRW5ITVJ?
TE-15 M3Pk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjCTWM2OD1zLkO2JI5O NYS2Uoh7W0GQR1XS
Ramos-2G6-4C10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLmTWM2OD1zLkS2JI5O Mn\ZV2FPT0WU
KU812 M1;6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7FfYNKSzVyPUKuNFEhdk1? NWfWO5JkW0GQR1XS
EW-1 NUXV[FJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X3dWlEPTB;Mj6xO{BvVQ>? NFrTWHRUSU6JRWK=
KS-1 NIjCUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fDW2lEPTB;Mj60OUBvVQ>? NXLFSW1lW0GQR1XS
SK-LMS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17icGlEPTB;Mj60PUBvVQ>? M1PzV3NCVkeHUh?=
TGBC1TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fs[GlEPTB;Mj62PUBvVQ>? NYHkXm1oW0GQR1XS
TE-6 NVf2dXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwN{egcm0> MnzPV2FPT0WU
ETK-1 NFnXVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoraTWM2OD1{LkiyJI5O MnvSV2FPT0WU
BE-13 M2T3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwOUmgcm0> MkT5V2FPT0WU
A3-KAW M122PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHENoxmUUN3ME2yMlk6KG6P NYDlXlVkW0GQR1XS
TE-10 NYPCN3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHOTWM2OD1|LkOgcm0> NXvJcGhTW0GQR1XS
DOHH-2 M3nK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDp[HZKSzVyPUOuN|Uhdk1? NFjiZZpUSU6JRWK=
ES6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFWVVKSzVyPUOuOFMhdk1? M3zqPXNCVkeHUh?=
OPM-2 NF65NJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHtTWM2OD12LkG1JI5O NHW5ZpRUSU6JRWK=
SH-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfrWoVFUUN3ME20MlM1KG6P MorVV2FPT0WU
NB13 NVHGVWxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\OVlZNUUN3ME20MlM3KG6P MWTTRW5ITVJ?
HUTU-80 NHXq[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwNEKgcm0> M1LrPXNCVkeHUh?=
CCRF-CEM MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzYTWM2OD12Lkm0JI5O MlO4V2FPT0WU
TGBC24TKB M{\VTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXuTWM2OD13LkWxJI5O M{K2THNCVkeHUh?=
697 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTIdolHUUN3ME22MlI5KG6P M1vmNHNCVkeHUh?=
J-RT3-T3-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\IfVdlUUN3ME22MlQ3KG6P M37OSXNCVkeHUh?=
KALS-1 NHrGZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTqTWM2OD14LkW2JI5O NHe3PGdUSU6JRWK=
no-10 NFv5dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fHe2lEPTB;Nz6yPUBvVQ>? M4TnfHNCVkeHUh?=
SK-NEP-1 NWC0S4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzkOHJKSzVyPUiuO|khdk1? M2fJd3NCVkeHUh?=
L-540 NHvHZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofKTWM2OD1zMD60NkBvVQ>? MVPTRW5ITVJ?
JiyoyeP-2003 M2ftfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jlOGlEPTB;MUCuPVQhdk1? NWfmcplFW0GQR1XS
HH NEjX[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\BXYdKSzVyPUGxMlM6KG6P NIf6e2JUSU6JRWK=
SR NX3EOWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fPZmlEPTB;MUGuOFUhdk1? NXTmUnFmW0GQR1XS
QIMR-WIL Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHrXnNKSzVyPUGxMlg2KG6P MYnTRW5ITVJ?
A4-Fuk MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjHVXBqUUN3ME2xN{4yOiCwTR?= NIDTbppUSU6JRWK=
CESS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7LXYFKSzVyPUGzMlE{KG6P NHjuW3dUSU6JRWK=
KE-37 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF4LkC3JI5O MYnTRW5ITVJ?
SK-UT-1 M3PxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr6Z|JKSzVyPUG2MlgyKG6P MXfTRW5ITVJ?
SIG-M5 NFmxOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITXR3dKSzVyPUG3MlI2KG6P MXTTRW5ITVJ?
HT NYr0XGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF5Lk[gcm0> NGLjS5FUSU6JRWK=
DEL MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPte2JuUUN3ME2xO{46QSCwTR?= M4TGdHNCVkeHUh?=
SK-PN-DW NUjJfJBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJyLkKzJI5O NHrYXm5USU6JRWK=
RPMI-8402 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJzLke3JI5O MWnTRW5ITVJ?
RPMI-6666 M4nuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLXRXN2UUN3ME2yOE41OiCwTR?= MVPTRW5ITVJ?
NCI-H720 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jERmlEPTB;MkWuOFEhdk1? NWH6e2NDW0GQR1XS
EW-16 M4PTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ4Lki3JI5O MXjTRW5ITVJ?
BL-70 NGS4eHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD1{OD6zPEBvVQ>? NGfUd|JUSU6JRWK=
SF126 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjnTWM2OD1|MD6zPEBvVQ>? MmXUV2FPT0WU
BC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNzLkK2JI5O M4fxOXNCVkeHUh?=
MHH-PREB-1 NGHRfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XSbmlEPTB;M{KuOFQhdk1? M4\xZXNCVkeHUh?=
A101D NHHDRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrjTWM2OD1|Mj62NkBvVQ>? NWnESI03W0GQR1XS
NMC-G1 NHezTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJPGlKSzVyPUOzMlY4KG6P MWnTRW5ITVJ?
LB1047-RCC M2\BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV71VYM{UUN3ME2zOE43QSCwTR?= NXvOV|ZNW0GQR1XS
EM-2 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESwR2ZKSzVyPUO4MlU{KG6P NEDFTI9USU6JRWK=
COLO-684 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTYd5ZKSzVyPUO5Mlghdk1? MU\TRW5ITVJ?
Becker NVXuS3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRzLkC1JI5O M1;MbHNCVkeHUh?=
BL-41 NUPBUoZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLETWM2OD12Mz62OkBvVQ>? M2DI[nNCVkeHUh?=
MDA-MB-134-VI M17CR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjsOpBKSzVyPUS0MlAzKG6P M1LxUXNCVkeHUh?=
L-363 NUjhW5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTR2LkezJI5O MV3TRW5ITVJ?
ECC4 M4rORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD12ND63PEBvVQ>? NGj3WlZUSU6JRWK=
A388 NXTRR494T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG0b4pHUUN3ME20OE45OiCwTR?= Mn;BV2FPT0WU
HEL NIXRU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDTIpKSzVyPUS5Mlc6KG6P NG\FTXRUSU6JRWK=
RKO NIfBZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS0PIhKSzVyPUWwMlI6KG6P NWW5eJJqW0GQR1XS
KINGS-1 NG\kWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5W2lEPTB;NUGuOVUhdk1? MnfIV2FPT0WU
EB-3 NFnzcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHIVWpoUUN3ME21Nk43PyCwTR?= NVLJ[GRnW0GQR1XS
ARH-77 NU\lblI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fJO2lEPTB;NUKuPEBvVQ>? M3LLdnNCVkeHUh?=
GCIY MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TPXGlEPTB;NUOuOFYhdk1? NFGwWmVUSU6JRWK=
NCI-H1304 M{P5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnacGJKSzVyPUW3MlIzKG6P MnrKV2FPT0WU
KARPAS-299 M4HKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm2dZc6UUN3ME22NU45OiCwTR?= NVnkcZRrW0GQR1XS
IA-LM Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrhRpZKSzVyPU[4MlE{KG6P NWHXNpE3W0GQR1XS
GI-1 NUnjOW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj0TWM2OD15MD6zPUBvVQ>? Mk\qV2FPT0WU
TE-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD15Nz6xO{BvVQ>? M4TwRXNCVkeHUh?=
LS-411N M{jw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD15Nz61O{BvVQ>? MmXPV2FPT0WU
no-11 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvIZ2xMUUN3ME24N{4zPCCwTR?= NHHuS4xUSU6JRWK=
MV-4-11 NGnWSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTh|LkezJI5O NY\6NlRkW0GQR1XS
BV-173 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTh|Lkm3JI5O MYrTRW5ITVJ?
CMK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTh2LkG2JI5O NF;SeVhUSU6JRWK=
LC4-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTh4LkeyJI5O M1\kfXNCVkeHUh?=
COR-L279 NIHoblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVXGlEPTB;OEeuNlUhdk1? MVzTRW5ITVJ?
NCI-H209 NFPzWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O5bWlEPTB;OEeuOFEhdk1? MYTTRW5ITVJ?
Raji M{TDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTh7LkeyJI5O NE\BPZlUSU6JRWK=
LB996-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\RcVYyUUN3ME25N{41OyCwTR?= MnqyV2FPT0WU
NCI-H526 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LNWmlEPTB;OUOuOVkhdk1? NUjk[ldNW0GQR1XS
KGN NVnE[GtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXTfmJKSzVyPUm2MlI6KG6P NWSwdFg6W0GQR1XS
MOLT-4 M{j5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtUFV1UUN3ME25Ok44QSCwTR?= Mn70V2FPT0WU
PF-382 NVm3bpVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PveWlEPTB;OU[uO|khdk1? MmHpV2FPT0WU
BC-3 NHjtdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q0OGlEPTB;OUmuNVghdk1? M4XYRnNCVkeHUh?=
KARPAS-422 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LaO2lEPTB;MUCyMlA6KG6P NULTcGd5W0GQR1XS
SBC-1 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G4VmlEPTB;MUC3Mlc2KG6P Mn3UV2FPT0WU
LC-1F M4P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPZWlEPTB;MUC4MlA2KG6P NUHKXGIxW0GQR1XS
GB-1 M2fQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyOT6wNkBvVQ>? Ml7UV2FPT0WU
SNB75 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfPXYFCUUN3ME2xNVkvPjlibl2= M{POc3NCVkeHUh?=
BB65-RCC MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTmTWM2OD1zMUmuPVMhdk1? MYjTRW5ITVJ?
NCI-N87 NV;KSVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqzZYRKSzVyPUGyNU46QCCwTR?= MkPRV2FPT0WU
IST-MEL1 M3:2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTpTWM2OD1zMkKuN|ghdk1? MYHTRW5ITVJ?
HOP-62 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHv[VJnUUN3ME2xNlYvQDlibl2= NI\FZ21USU6JRWK=
ACN MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fxfGlEPTB;MUS2Mlc2KG6P NYrjdFdQW0GQR1XS
DMS-114 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2VYFbUUN3ME2xOVAvPjdibl2= NXfybHJXW0GQR1XS
MLMA M1riO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LhfmlEPTB;MUW5Mlg5KG6P NGG2O2FUSU6JRWK=
HT-144 NGDKfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmeyTWM2OD1zNkWuOFMhdk1? MlHXV2FPT0WU
C2BBe1 NEizZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILWcGhKSzVyPUG2O{44PiCwTR?= Mn\JV2FPT0WU
L-428 M4jhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP0TWM2OD1zN{euO{BvVQ>? NIjhUG9USU6JRWK=
DU-4475 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF6Nz62PEBvVQ>? NUn0bmJoW0GQR1XS
CP67-MEL M3;1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrmS4t7UUN3ME2xPVkvOzhibl2= NEfpRlRUSU6JRWK=
MEG-01 M3zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyMT65OkBvVQ>? NXKyeIlOW0GQR1XS
IST-SL2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzJfFM4UUN3ME2yNFgvPjNibl2= M3HscnNCVkeHUh?=
ES8 M3LLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPn[FRKSzVyPUKyOU46PCCwTR?= MWPTRW5ITVJ?
COLO-800 M3HYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzFelN4UUN3ME2yN|UvOjhibl2= M{LSbHNCVkeHUh?=
MFH-ino MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGeVJiUUN3ME2yN|UvQDRibl2= MoPXV2FPT0WU
OVCAR-4 NHnoe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ|Nz6yOEBvVQ>? MlTSV2FPT0WU
PSN1 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\UeGlEPTB;MkSyMlcyKG6P MYHTRW5ITVJ?
EW-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOy[ppKSzVyPUK0N{4yKG6P MXHTRW5ITVJ?
HCC1599 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX2NohKSzVyPUK2NU41PyCwTR?= NHrHc|ZUSU6JRWK=
SJSA-1 NEfSWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPT5BsUUN3ME2yO|EvPDZibl2= NHW3SXlUSU6JRWK=
ST486 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n4[2lEPTB;Mkm2MlE1KG6P M4HHPXNCVkeHUh?=
NOMO-1 NWW0XGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvnfZpKSzVyPUOwNE4zOSCwTR?= NFLYdm5USU6JRWK=
MN-60 NVHQRoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf1dm84UUN3ME2zNFUvOzJibl2= NH3kS2lUSU6JRWK=
HCC1187 M{j2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzPPIlKSzVyPUOwO{4zPSCwTR?= NVq1eY9YW0GQR1XS
SW982 NVrGc5VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T3W2lEPTB;M{G0Mlc2KG6P NFnqXpRUSU6JRWK=
LB647-SCLC MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjcIRKSzVyPUOyPE44OSCwTR?= M{DIWHNCVkeHUh?=
HC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN|NT61JI5O MUfTRW5ITVJ?
EHEB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32wRWlEPTB;M{O3MlUzKG6P M3\UfXNCVkeHUh?=
TUR Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP6TWM2OD1|NkOuPVUhdk1? M2P4eHNCVkeHUh?=
LU-139 NI\Vb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDTWM2OD1|N{iuNFIhdk1? Mm\2V2FPT0WU
NB1 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13wNmlEPTB;M{i0MlQ2KG6P MYPTRW5ITVJ?
BB30-HNC NHfuXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2cGlEPTB;M{i4MlMzKG6P MoD3V2FPT0WU
HAL-01 NGXURXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1|OEmuNlYhdk1? MmTtV2FPT0WU
K5 NVPtblhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS1SohKSzVyPUSxNU4{PyCwTR?= MX\TRW5ITVJ?
MZ2-MEL MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3CTWM2OD12MUOuOlQhdk1? MXnTRW5ITVJ?
RXF393 NHjFXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmzTWM2OD12MU[uOFUhdk1? M4j0bnNCVkeHUh?=
NCI-H1648 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvrdpF1UUN3ME20NVcvPTNibl2= MnP2V2FPT0WU
TE-12 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknuTWM2OD12M{SuNlYhdk1? NXHZcFMxW0GQR1XS
EoL-1- MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTR|Nz65PEBvVQ>? NG\sV3BUSU6JRWK=
JAR NI\vS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\2TWM2OD12M{iuOlIhdk1? MW\TRW5ITVJ?
DSH1 NY\CZos4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fmWWlEPTB;NEW4MlkyKG6P MWXTRW5ITVJ?
NCI-H187 NVu3XG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL0b5JKSzVyPUS2Nk45OSCwTR?= NGDNZ3ZUSU6JRWK=
HCE-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnZWY5KSzVyPUS3O{43PiCwTR?= Mn:wV2FPT0WU
8-MG-BA NUjlNW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTV6MT61NkBvVQ>? MVXTRW5ITVJ?
KLE MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X5TGlEPTB;NUi1MlIhdk1? MXvTRW5ITVJ?
KNS-42 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPhbmRFUUN3ME21PFYvQDFibl2= NFO0UmNUSU6JRWK=
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTDTWM2OD14MEmuO|Qhdk1? MXXTRW5ITVJ?
GDM-1 M{HhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD14MUSuNFkhdk1? NFL1V|ZUSU6JRWK=
TE-1 NFLzfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjT[3N7UUN3ME22OFYvOTJibl2= MYDTRW5ITVJ?
BT-474 M13mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZ2Nz6wOkBvVQ>? MmLGV2FPT0WU
KARPAS-45 NXHsc5NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLFTWM2OD14NEeuOkBvVQ>? NF;6Om5USU6JRWK=
MOLT-16 M2DxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZ2Nz65N{BvVQ>? MlTvV2FPT0WU
KURAMOCHI NEP1UodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;qOnhbUUN3ME22OVcvPTFibl2= MXXTRW5ITVJ?
K-562 M3;nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj2cGZKSzVyPU[2PU42OSCwTR?= NFnlTVZUSU6JRWK=
EKVX NIW0S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\YSWlEPTB;NkeyMlcyKG6P NH3G[nFUSU6JRWK=
GAK NVfMVnNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3UVZ7UUN3ME22O|UvOyCwTR?= NFzJ[mFUSU6JRWK=
NCI-SNU-5 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLl[otHUUN3ME22PVAvODFibl2= MWfTRW5ITVJ?
NCI-H2126 M4LJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTd{Nj64O{BvVQ>? Mn3CV2FPT0WU
CTV-1 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H5eGlEPTB;N{S0Mlkhdk1? MlfxV2FPT0WU
SW962 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLPdVFGUUN3ME23OFgvPDRibl2= MnfCV2FPT0WU
MONO-MAC-6 M{P3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITMV3pKSzVyPUe1Ok46OyCwTR?= M4rydnNCVkeHUh?=
NCI-H748 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;5c3FtUUN3ME23OVgvQTlibl2= NHHzXW5USU6JRWK=
NCI-H524 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTd6MD63N{BvVQ>? NEnCcHdUSU6JRWK=
LS-123 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXThSnI1UUN3ME23PVUvPjlibl2= M4\qZ3NCVkeHUh?=
NB7 NVK5[pd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRThzND6xOEBvVQ>? M2fKW3NCVkeHUh?=
LS-1034 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3tUFFKSzVyPUiyPE46QCCwTR?= M{fW[nNCVkeHUh?=
TE-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTh6Mz61OkBvVQ>? MYLTRW5ITVJ?
A704 NHS0[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTPTWM2OD16OUmuNVUhdk1? M4DWXHNCVkeHUh?=
TK10 NVzhR4pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DxZ2lEPTB;OUG2MlA{KG6P M33OW3NCVkeHUh?=
NCI-H345 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf3T|JKSzVyPUm0N{4zOiCwTR?= NX;IZoJ2W0GQR1XS
CGTH-W-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PCemlEPTB;OUS4MlE{KG6P M1nzNnNCVkeHUh?=
NCI-H510A NHjUS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLpVFlKSzVyPUm4OU4yOiCwTR?= M3fPSHNCVkeHUh?=
NCI-H1963 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn3XJJKSzVyPUGuNFMzQTJizszN NH;MOpRUSU6JRWK=
SCC-3 NUTrVGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljoTWM2OD1zLkCzOFE1KM7:TR?= NUP5e4F3W0GQR1XS
EW-11 NVTpTFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rUbmlEPTB;MT6wPFc1OyEQvF2= M2HQenNCVkeHUh?=
CPC-N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;BepNKSzVyPUGuNFg5KM7:TR?= NGnFXHVUSU6JRWK=
NCI-H1417 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPNeYtLUUN3ME2xMlEzOjZizszN NWjlPVlZW0GQR1XS
DG-75 NXjVd5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;jTWM2OD1zLkG2Nlg2KM7:TR?= NEO4XXZUSU6JRWK=
HD-MY-Z M{i1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DicWlEPTB;MT6xOlQyPiEQvF2= NVPBR3V4W0GQR1XS
ATN-1 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3BWXNXUUN3ME2xMlI3OjB7IN88US=> M4P2T3NCVkeHUh?=
KM-H2 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\BTWM2OD1zLkK2OFA5KM7:TR?= NHXxV|JUSU6JRWK=
NCI-H2081 M{jyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P4bmlEPTB;MT6yOlY{PyEQvF2= M33qR3NCVkeHUh?=
HL-60 M{XIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S1c2lEPTB;MT6yOlk2QSEQvF2= MkG2V2FPT0WU
DB Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HacmlEPTB;MT6yO|I1OiEQvF2= MWjTRW5ITVJ?
NCI-H1522 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TMNWlEPTB;MT6yPFg5PyEQvF2= NYWyZ3V{W0GQR1XS
AM-38 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XiXGlEPTB;MT6zNFczKM7:TR?= NVLWTZpEW0GQR1XS
NCI-H446 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwM{KxNlEh|ryP NGT5e4tUSU6JRWK=
SU-DHL-1 NWLJZWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ZTWM2OD1zLkOyPFAyKM7:TR?= NWewcFFlW0GQR1XS
NH-12 NUP6VItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnO25KSzVyPUGuN|Y{PzRizszN M{jpU3NCVkeHUh?=
DMS-79 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[ybWlEPTB;MT6zOlg3PiEQvF2= NGf1cG5USU6JRWK=
NCI-H716 NHTS[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfIbVR1UUN3ME2xMlM5QTh4IN88US=> M1LIRnNCVkeHUh?=
ML-2 M1LpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3Ge|hDUUN3ME2xMlQyPTJ7IN88US=> NI\yO4ZUSU6JRWK=
NB10 M4T1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjr[JBKSzVyPUGuOFY3OzJizszN NXfGOINOW0GQR1XS
ONS-76 NIHFSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K3RmlEPTB;MT61N|U3QSEQvF2= MVrTRW5ITVJ?
LOUCY NHjVcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;OVo1yUUN3ME2xMlU1PjV5IN88US=> MX7TRW5ITVJ?
SCLC-21H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwNUi1PFIh|ryP NWTiXnljW0GQR1XS
TGW MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4TY1KSzVyPUGuOlM6PzVizszN MkfoV2FPT0WU
LXF-289 M3[xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS3U49KSzVyPUGuO|MzPjhizszN NHr4VnpUSU6JRWK=
BB49-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPHTWM2OD1zLkezOVg3KM7:TR?= NHT5PGRUSU6JRWK=
NCI-H747 NF7kS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KzZWlEPTB;MT63OVM1PiEQvF2= M2rEdnNCVkeHUh?=
LU-165 NV3wNXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwOES5PFYh|ryP M3HxO3NCVkeHUh?=
OMC-1 NUewb4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TNeWlEPTB;MT65OVA3PiEQvF2= Ml\UV2FPT0WU
RCC10RGB NYLUcGZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nJb2lEPTB;MT65OVgyPyEQvF2= M2Ljc3NCVkeHUh?=
SW684 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5U4tKSzVyPUGuPVYxQTlizszN NGH4TolUSU6JRWK=
TE-8 NVv2fIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWyXGFKSzVyPUKuNFU2PTlizszN MUHTRW5ITVJ?
SK-N-DZ MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\HTWM2OD1{LkGzNlc1KM7:TR?= M{HsS3NCVkeHUh?=
EVSA-T NU\IbYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInX[pVKSzVyPUKuNVc{OTVizszN M{DTOnNCVkeHUh?=
KASUMI-1 M2\CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HRcWlEPTB;Mj6xPFgyPSEQvF2= MVrTRW5ITVJ?
NKM-1 NGCxdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nrTmlEPTB;Mj6yOVQ4OiEQvF2= NWTJe3liW0GQR1XS
CAL-148 M1e0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37jfWlEPTB;Mj6zN|YyPCEQvF2= M1PuWXNCVkeHUh?=
NCI-H64 M4\EPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLDTWM2OD1{LkO0NlMzKM7:TR?= MWnTRW5ITVJ?
KNS-81-FD MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjWVXJKSzVyPUKuN|Y3OiEQvF2= MmP0V2FPT0WU
KM12 NXjiVZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwNEC4N|kh|ryP M4TJXHNCVkeHUh?=
SW954 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXFd4pIUUN3ME2yMlQ4Pzd7IN88US=> MXnTRW5ITVJ?
NCI-H1395 NHrsdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LNRWlEPTB;Mj61NlY1PSEQvF2= NFHXbYRUSU6JRWK=
DJM-1 NIHxOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fyRWlEPTB;Mj62NFY{KM7:TR?= NHTUZlJUSU6JRWK=
COLO-668 M4TsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLITot1UUN3ME2yMlgzPjl3IN88US=> MmrFV2FPT0WU
NCI-H1436 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXjSoRKSzVyPUKuPFU3OTVizszN MU\TRW5ITVJ?
LB2241-RCC MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwOE[4N|kh|ryP MUjTRW5ITVJ?
GT3TKB M2X4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwOEmwOVUh|ryP Mn\3V2FPT0WU
COLO-824 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELtUndKSzVyPUKuPFk4PjhizszN MUHTRW5ITVJ?
ES1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvqTWM2OD1{Lki5PFc6KM7:TR?= NVnjcWdQW0GQR1XS
LB771-HNC NHexSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmraTWM2OD1{LkmwPVQ3KM7:TR?= NE\EfWZUSU6JRWK=
GI-ME-N Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwMEC5NFQh|ryP MknJV2FPT0WU
NALM-6 M3;rbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O0[WlEPTB;Mz6wNFk{OyEQvF2= NInFUVJUSU6JRWK=
LU-134-A M1v1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD1|LkC1OFI2KM7:TR?= M3rZenNCVkeHUh?=
DMS-153 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLITWM2OD1|LkC1PFI1KM7:TR?= MXTTRW5ITVJ?
MZ1-PC MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;h[XJKSzVyPUOuNFkxPzhizszN NFLNd|VUSU6JRWK=
NCI-H1155 NH;1e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLkTWM2OD1|LkGxOlEh|ryP MX\TRW5ITVJ?
CAS-1 NF\4UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3HbWJTUUN3ME2zMlE{PzB5IN88US=> NIXTd2lUSU6JRWK=
D-502MG MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS0WphKSzVyPUOuNVQ{QSEQvF2= NG\FT2FUSU6JRWK=
NCI-H2141 NIrpPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGxd4tKSzVyPUOuNVc1PTJizszN MXPTRW5ITVJ?
NB6 NX;I[|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e5OGlEPTB;Mz6xPFI2QSEQvF2= NXv6eHFOW0GQR1XS
NCCIT M3P5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILBN5dKSzVyPUOuNlE5ODlizszN MVvTRW5ITVJ?
NB69 NWmwS2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwM{G4PVEh|ryP NVy3ToNLW0GQR1XS
JVM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TiNmlEPTB;Mz6zOlQ{OyEQvF2= NV33SnhoW0GQR1XS
K052 NF\CPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\WTWM2OD1|LkO3PVY5KM7:TR?= NX7kNoJyW0GQR1XS
HCC2157 NFvyRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwNUOyNlgh|ryP MVnTRW5ITVJ?
KMOE-2 NVPncnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwNUSyOFIh|ryP MUfTRW5ITVJ?
SF268 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLUTWM2OD1|LkexOVU1KM7:TR?= NHKxN4RUSU6JRWK=
CHP-126 M2\aUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nwe2lEPTB;Mz63OlQ2QCEQvF2= NWLyc2M5W0GQR1XS
CP66-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwN{mwPVQh|ryP NY\EPVNQW0GQR1XS
NCI-H69 M4jzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLjSIdKSzVyPUSuNFE6OzZizszN MoXIV2FPT0WU
A253 M3vTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnNe2lRUUN3ME20MlAzOTBzIN88US=> MWDTRW5ITVJ?
NB14 NGTzclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXpTWM2OD12LkGwOFc6KM7:TR?= NFnSRWdUSU6JRWK=
NCI-H1694 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Gxb2lEPTB;ND6xN|EyOiEQvF2= Mk\6V2FPT0WU
NCI-H2196 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nC[mlEPTB;ND6xO|E3QSEQvF2= M2LWOXNCVkeHUh?=
TE-9 NHPQSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnZc2hKSzVyPUSuNVc2QDJizszN NHnBPVFUSU6JRWK=
D-283MED NVe4eXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRwMUi4OEDPxE1? NULPcVZWW0GQR1XS
OCI-AML2 NWDQcpo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XscWlEPTB;ND6xPVQ5QSEQvF2= NVfCZnZFW0GQR1XS
D-263MG NYTG[mJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\hWmlEPTB;ND6yNlk3OSEQvF2= Mn\hV2FPT0WU
MPP-89 NHrVXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnyTWM2OD12LkK3N|A1KM7:TR?= NXfQTFdIW0GQR1XS
LAMA-84 NWnISoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfOdHJQUUN3ME20MlMxPDJzIN88US=> MlrMV2FPT0WU
LB373-MEL-D NX3aO5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\lWI04UUN3ME20MlM3Pzh7IN88US=> MnTMV2FPT0WU
UACC-257 NHnXbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvOTWM2OD12LkO5OVM1KM7:TR?= MX7TRW5ITVJ?
MC-CAR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJUXFbUUN3ME20MlQ{QTlizszN MX3TRW5ITVJ?
COLO-320-HSR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfxTWM2OD12LkS0OFI4KM7:TR?= M1\4XHNCVkeHUh?=
P30-OHK NGHZdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2bmlEPTB;ND62OlU5OSEQvF2= MWDTRW5ITVJ?
UACC-812 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PmW2lEPTB;ND62PVE3OSEQvF2= MUHTRW5ITVJ?
CTB-1 M{ixbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwN{G1OVUh|ryP NFXCeWJUSU6JRWK=
ALL-PO M3j4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn0dYgzUUN3ME20Mlg1ODd5IN88US=> Ml:4V2FPT0WU
SK-MEL-2 M{Hx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXoTWM2OD12Lki2PVU2KM7:TR?= NFq4Oo5USU6JRWK=
TC-YIK NYDkbIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwOUe5OFIh|ryP MYPTRW5ITVJ?
NCI-H1882 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK3TWM2OD13LkCyNFAyKM7:TR?= MYfTRW5ITVJ?
MHH-CALL-2 NIfVR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXTWM2OD13LkC1NFQzKM7:TR?= NVvDXoRtW0GQR1XS
U-87-MG NYG5W5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjY[2VYUUN3ME21MlA6PDZ4IN88US=> MnzmV2FPT0WU
NCI-H1092 M2KyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnm[VM{UUN3ME21MlI3PTV3IN88US=> MYTTRW5ITVJ?
TE-441-T NEPtemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwMke4NkDPxE1? MX3TRW5ITVJ?
SK-MEL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHsfWRKSzVyPUWuNlkxPDRizszN NHW1fYNUSU6JRWK=
EW-22 M1zu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwMkm0OlYh|ryP NXTLUFhTW0GQR1XS
MZ7-mel M3fPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTVwNEC2PVEh|ryP NHLvWotUSU6JRWK=
LP-1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXibYZKSzVyPUWuOFEzQTFizszN MoHuV2FPT0WU
NCI-SNU-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7LUHN2UUN3ME21MlY1ODd2IN88US=> MlzsV2FPT0WU
LU-65 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwN{[zO|Mh|ryP NYD6UlFqW0GQR1XS
CW-2 NUG1SW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTVwOEW5OVkh|ryP MVHTRW5ITVJ?
WSU-NHL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHKcpF[UUN3ME21Mlk2OTd2IN88US=> NUDDNolJW0GQR1XS
IST-MES1 NIrhVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnROHZKSzVyPUWuPVU1PDNizszN MXzTRW5ITVJ?
U-266 NEHyN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO4TWM2OD13Lkm4NlAzKM7:TR?= MWHTRW5ITVJ?
TALL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH3NphiUUN3ME22MlE1Pjh6IN88US=> MUHTRW5ITVJ?
Calu-6 NF3heodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXEW4ZKSzVyPU[uNVU{OTZizszN MUjTRW5ITVJ?
MMAC-SF NXe0ZpBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjFTWM2OD14LkG4OVU3KM7:TR?= NXjnd4lKW0GQR1XS
NCI-H82 NHTTXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ywXGlEPTB;Nj6yNFQ5QSEQvF2= MXHTRW5ITVJ?
RS4-11 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn0WYZiUUN3ME22MlI2QDl5IN88US=> MYDTRW5ITVJ?
SNU-C2B NUnLOmRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:0SI9JUUN3ME22MlQxQTZ7IN88US=> MYDTRW5ITVJ?
BOKU NU\FVpdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljQTWM2OD14LkS3OVk4KM7:TR?= NIH1U5NUSU6JRWK=
C8166 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwNUW5NVIh|ryP M{TtSXNCVkeHUh?=
D-247MG NEDacGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL5TWM2OD15LkC0N|Q4KM7:TR?= MV3TRW5ITVJ?
EW-18 MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrURYIzUUN3ME23MlA4Ojl{IN88US=> M3nPNXNCVkeHUh?=
KG-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwNkK3N|gh|ryP Moq5V2FPT0WU
REH NH7jcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDyN2h4UUN3ME23MlY5OTB7IN88US=> Mn;vV2FPT0WU
U-698-M NXL1[ZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPMTWM2OD15Lki0N|E2KM7:TR?= NWPC[3hEW0GQR1XS
KP-N-RT-BM-1 NG\nW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO3VI13UUN3ME23Mlk{ODJ7IN88US=> M{C2[nNCVkeHUh?=
MS-1 NFn3UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHCSWxKSzVyPUeuPVYxPDFizszN MXXTRW5ITVJ?
SNU-C1 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrhcmpQUUN3ME23Mlk5OTl{IN88US=> MmfvV2FPT0WU
SK-MM-2 M1XMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH74XJVKSzVyPUiuNlYxPjVizszN M{\mUHNCVkeHUh?=
LAN-6 NFLyPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiycmVKSzVyPUiuN|AxODFizszN MXnTRW5ITVJ?
NEC8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMSHlKSzVyPUiuN|A3QTFizszN MX;TRW5ITVJ?
NCI-H1770 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD16LkO4NFAzKM7:TR?= MXTTRW5ITVJ?
D-336MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfyTWM2OD16LkSwNVE3KM7:TR?= MXjTRW5ITVJ?
COLO-829 NH;XVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33QZWlEPTB;OD60PFg4QSEQvF2= M4XTUXNCVkeHUh?=
LS-513 NV3OOlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwNUm1PVkh|ryP NWPoboNOW0GQR1XS
YT NEHRZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXoTWM2OD16Lk[yOFI4KM7:TR?= MUXTRW5ITVJ?
EW-24 M4TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRThwN{[1OEDPxE1? NHPpXXFUSU6JRWK=
IST-SL1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XEZmlEPTB;OD64OlU1OyEQvF2= M{L3e3NCVkeHUh?=
CA46 NVi3[pFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XxOGlEPTB;OD65OVA6QCEQvF2= MVTTRW5ITVJ?
NCI-H1838 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwOUi2NFIh|ryP NG\IZ4xUSU6JRWK=
NCI-H719 NGjic29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XId2lEPTB;OT6yOVI4QSEQvF2= MYTTRW5ITVJ?
HCE-T M{fxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnlUJZKSzVyPUmuN|A5PTFizszN NY\6eXpDW0GQR1XS
A498 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPuNmFKSzVyPUmuN|YyOjRizszN MWHTRW5ITVJ?
LB831-BLC M3rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK0fIdJUUN3ME25Mlc3PTJzIN88US=> Mn;wV2FPT0WU
SKM-1 M{TYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmeFJKSzVyPUmuPFU6PjNizszN NX;SSGdLW0GQR1XS
THP-1 M4WwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnyN5ZKSzVyPUmuPVY6OThizszN NHfqc3BUSU6JRWK=
SHP-77 NVfBXFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFyLkSwO{DPxE1? MWnTRW5ITVJ?
EW-3 M2nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnWTWM2OD1zMD62Nlg6KM7:TR?= NIjl[WdUSU6JRWK=
KY821 NX7tWXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFyLke2N{DPxE1? NGfUNIhUSU6JRWK=
NCI-SNU-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrw[YJDUUN3ME2xNU4xOjF5IN88US=> MmPrV2FPT0WU
HCC2218 NETIfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kd3ZKSzVyPUGxMlM6QDZizszN M4LPfnNCVkeHUh?=
IM-9 NF\yboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPsTGltUUN3ME2xNU42OTB4IN88US=> NXzzcpdFW0GQR1XS
NCI-H889 NF\vOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfXbXR6UUN3ME2xNU42OzF|IN88US=> MUXTRW5ITVJ?
HDLM-2 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF{LkSxOVkh|ryP MUHTRW5ITVJ?
LB2518-MEL M{PWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDj[oN3UUN3ME2xNk43QDF3IN88US=> MUDTRW5ITVJ?
NCI-H23 NVXLT|A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF|LkK0NlUh|ryP MnjGV2FPT0WU
NB17 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\WfIpKSzVyPUGzMlQ2PzlizszN MkDYV2FPT0WU
NCI-H322M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF2LkSwOlgh|ryP M4PEWXNCVkeHUh?=
SUP-T1 NXPxXmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XJfmlEPTB;MUSuOFE{KM7:TR?= NIPw[3JUSU6JRWK=
ES3 NVywSIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLiTWM2OD1zNT6wO|A{KM7:TR?= M3;UOXNCVkeHUh?=
ES5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7VWnBvUUN3ME2xOU4xPzh5IN88US=> NWn3[o1[W0GQR1XS
NCI-H1650 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\vUGlEPTB;MUWuOFk4QSEQvF2= M1jrfXNCVkeHUh?=
NCI-H226 M4rGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD1zNT64O|Y5KM7:TR?= M3HXRnNCVkeHUh?=
COR-L88 NFvQd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF4LkOxOEDPxE1? M1T1dXNCVkeHUh?=
SCC-15 NHi0XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMbWlEPTB;MU[uN|g3QSEQvF2= MlLaV2FPT0WU
GOTO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTVfYpTUUN3ME2xOk41Pzl|IN88US=> NHLrcoVUSU6JRWK=
SIMA M3Xscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPqXIlKSzVyPUG2MlQ5ODJizszN NHnvfHFUSU6JRWK=
NCI-H1299 NYLqNJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZSpB[UUN3ME2xO{4yPTlzIN88US=> M1\Qc3NCVkeHUh?=
NCI-H1581 NUe5bVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5LkSyNVkh|ryP NGS2W4xUSU6JRWK=
MHH-NB-11 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jUbWlEPTB;MUeuPVY5OyEQvF2= Ml[2V2FPT0WU
MFM-223 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfSTIZpUUN3ME2xPE4xPTN6IN88US=> MVrTRW5ITVJ?
ES7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13lUGlEPTB;MUiuOVQ{OSEQvF2= NWrucYRsW0GQR1XS
JVM-3 NGntOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LNXmlEPTB;MUiuO|E4KM7:TR?= NV7pZoRjW0GQR1XS
RL MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;TcIJEUUN3ME2yNE4{QDhizszN MYDTRW5ITVJ?
EC-GI-10 NETYVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm0SmRKSzVyPUKxMlIxPDFizszN NVrM[I9WW0GQR1XS
LNCaP-Clone-FGC M4rWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XaXGlEPTB;MkGuOlc3QCEQvF2= MVLTRW5ITVJ?
IMR-5 NX;rdnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm2TWM2OD1{MT64OFk1KM7:TR?= NFXYWVFUSU6JRWK=
KP-N-YS NWjGOph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;L[JdLUUN3ME2yNU45PzVizszN NHHMb2xUSU6JRWK=
Mo-T M3vR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\vXmlEPTB;MkKuNlE5PSEQvF2= MWfTRW5ITVJ?
NCI-H128 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD1{Mz61PFU{KM7:TR?= NX;nNZY3W0GQR1XS
RH-1 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hPIZ1UUN3ME2yN{44QDZ4IN88US=> M1;PT3NCVkeHUh?=
NCI-H2171 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{njfGlEPTB;MkSuNlQ5PSEQvF2= NEm5ToJUSU6JRWK=
RPMI-8866 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ4Lke0NkDPxE1? MXfTRW5ITVJ?
SK-N-FI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\FU2lEPTB;MkeuN|gyOSEQvF2= M4nCb3NCVkeHUh?=
LOXIMVI M1HqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jlW2lEPTB;MkeuPFA2OSEQvF2= NWLB[2ZkW0GQR1XS
P31-FUJ NIm5RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;zTWM2OD1|MT61N|c1KM7:TR?= NXu3epJrW0GQR1XS
KMS-12-PE NVfyfZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorCTWM2OD12OT61N|AzKM7:TR?= NGXpXotUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00977691 Active not recruiting Peripheral Blood Stem Cell Transplantation|Anemia Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath ) National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) September 9 2009 Phase 1|Phase 2
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01885689 Active not recruiting Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome City of Hope Medical Center|National Cancer Institute (NCI) January 8 2014 Phase 2
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID